Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa

被引：0
|
作者：
Konen, Franz Felix [1 ]
Pfeuffer, Steffen [2 ]
Jendretzky, Konstantin Fritz [1 ]
Gehring, Klaus [3 ]
Elias-Hamp, Birte
Suehs, Kurt-Wolfram [1 ]
Pawlitzki, Marc [4 ]
Meuth, Sven [4 ]
Kleinschnitz, Christoph [5 ,6 ]
Pul, Refik [5 ,6 ]
Skripuletz, Thomas [1 ]
机构：
[1] Hannover Med Sch, Dept Neurol, Hannover, Germany
[2] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Neurol, Giessen, Germany
[3] Neurozentrum Klosterforst, Itzehoe, Germany
[4] Heinrich Heine Univ Duesseldorf, Univ Hosp Duesseldorf, Dept Neurol, Dusseldorf, Germany
[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany
[6] Ctr Translat Neuro & Behav Sci C TNBS, Essen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P293/939
引用
收藏
页码：328 / 330
页数：3
相关论文
共 50 条
  • [41] Improvements in quality of life over 2 years in patients treated with cladribine tablets for highly active relapsing multiple sclerosis: Final analysis of CLARIFY-MS
    Solari, A.
    Montalban, X.
    Lechner-Scott, J.
    Piehl, F.
    Brochet, B.
    Langdon, D.
    Hupperts, R.
    Selmaj, K.
    Havrdova, E. K.
    Patti, F.
    Brieva, L.
    Maida, E. M.
    Alexandri, N.
    Smyk, A.
    Nolting, A.
    Keller, B.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 203 - 204
  • [42] Long-term Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis: Analysis of Real World Data From the Italian Multiple Sclerosis Registry (CLARINET-MS)
    Patti, Francesco
    Visconti, Andrea
    Capacchione, Antonio
    Trojano, Maria
    NEUROLOGY, 2020, 94 (15)
  • [43] Preexisting humoral immunity for measles and varicella zoster in patients with multiple sclerosis after exposure to anti-CD20 therapies: does protection wane?
    Carvajal, Rene
    Tur, Carmen
    Carbonell, Pere
    Cobo Calvo, Alvaro
    Arino, Helena
    Aroca Alisina, Montse
    Arrambide, Georgina
    Bollo, Luca
    Bravo, Gabriel
    Cardenas-Robledo, Simon
    Castillo-Justribo, Joaquin
    Comabella, Manuel
    Esperalba, Juliana
    Galan, Ingrid
    Sarreon, Alexis
    Guio-Sanchez, Claudia
    La Puma, Delon
    Midaglia, Luciana
    Pappolla, Agustin
    Robles Sanchez, Miguel Angel
    Rodriguez-Barranco, Marta
    Rodriguez, Breogan
    Rio, Jordi
    Tagliani, Paula
    Vidal-Jordana, Angela
    Vilaseca, Andreu
    Zabalza, Ana
    Sastre-Garriga, Jaume
    Montalban, Xavier
    Tintore, Mar
    Otero-Romero, Susana
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 29 - 31
  • [44] Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?
    Avasarala, Jagannadha
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (12) : 3094 - 3096
  • [45] Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
    Elgenidy, Anas
    Abdelhalim, Nagham Nader
    Al-kurdi, Mohammed Al-mahdi
    Mohamed, Lobna A.
    Ghoneim, Mohamed M.
    Fathy, Ahmed Wagdy
    Hassaan, Hazem Khaled
    Anan, Ahmed
    Alomari, Omar
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [46] Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic
    Stepien, Adam
    Pogoda-Wesolowska, Aleksandra
    Tokarz-Kupczyk, Elzbieta
    Slowik, Agnieszka
    Puz, Przemyslaw
    Adamczyk-Sowa, Monika
    Kurkowska-Jastrzebska, Iwona
    Kulakowska, Alina
    Chorazy, Monika
    Piasecka-Stryczynska, Karolina
    Jamroz-Wisniewska, Anna
    Bartosik-Psujek, Halina
    Rejdak, Konrad
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2023, 57 (04) : 371 - 378
  • [47] Disease Modifying Therapy Choice in People with Multiple Sclerosis in The Era of Covid: Characterizing Outcomes in Patients who Switched from anti-CD20 Therapies to Diroximel Fumarate
    Kaczmarek, O.
    Sethi, A.
    Teng, E.
    Bumstead, B.
    Buhse, M.
    Zarif, M.
    Scott, N.
    Gocke, A.
    Mendoza, J. P.
    Gudesblatt, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 78 - 79
  • [48] Age-Stratified Real World Outcomes in People with Relapsing Multiple Sclerosis over 50 Years of Age After Switching to Cladribine Tablets from High Efficacy Disease Modifying Therapies
    Okuda, Darin
    Livingston, Terrie
    Moog, Tatum
    Smith, Alexander
    Burgess, Katy
    Wright, Crystal
    Hardeman, Paula
    Sguigna, Peter
    Tardo, Lauren
    Horton, Lindsay
    Greenberg, Benjamin M.
    Blackburn, Kyle
    Munoz, Shanan
    Chandler, Angela
    Piette, Elizabeth
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 385 - 386
  • [49] Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis
    Steinman, Lawrence
    Fox, Edward
    Hartung, Hans-Peter
    Cree, Bruce
    Alvarez, Enrique
    Qian, Peiqing
    Wray, Sibyl
    Robertson, Derrick
    Huang, Deren
    Selmaj, Krzystof
    Wynn, Daniel
    Weiss, Michael
    Bosco, Jenna
    Power, Sean
    Mok, Koby
    NEUROLOGY, 2020, 94 (15)
  • [50] Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
    Brochet, Bruno
    Hupperts, Raymond
    Langdon, Dawn
    Solari, Alessandra
    Piehl, Fredrik
    Lechner-Scott, Jeannette
    Montalban, Xavier
    Selmaj, Krzysztof
    Valis, Martin
    Rejdak, Konrad
    Havrdova, Eva K.
    Patti, Francesco
    Alexandri, Nektaria
    Nolting, Axel
    Keller, Birgit
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
12345